Key Drivers
- Strong FCF
- High leverage
- Accounting impairments
AIAI Summary
Viatris's strategic pivot toward higher‑margin branded medicines, backed by solid near‑term FCF, makes it a high‑variance turnaround with meaningful upside if management executes the $650M savings, achieves timely Indore remediation and secures key NDA approvals — but prolonged Indore issues, missed savings or regulatory denials would quickly erode EBITDA and strain its heavy leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •High leverage
- •Accounting impairments
VTRS generates strong free cash flow and pays a supported dividend despite large annual accounting losses, significant leverage, and one‑time equity impairments that depress profitability even as quarterly EBITDA shows operational improvement.
Price Behavior
Key Price Behavior Insights:
- •Short-term bearish
- •Below moving average
- •Increased volatility
Over the last month VTRS has dropped about 16% to $13.20 and sits below the last-month 21-day SMA (~$14.48), signaling short-term bearish momentum with resistance at $15.60–$15.90 and support at $13.20 and $12.27–$12.98.
Increased volatility with a ~16% decline from early
Sentiment & News
Key News Insights:
- •Brands & China
- •Cost-savings plan
- •Manufacturing disruption
Viatris beat 2025 targets with $14.3B revenue and a Q4 EPS beat, announced $650M in cost saves with $250M reinvestment, kept dividends while flagging 2026 profit pressure from an India plant fire and advancing key pipeline/regulatory milestones.
Expect near-term share pressure from the India plant disruption but potential stabilization and upside as cost savings, dividends and pipeline launches materialize
Similar Companies in Healthcare
Other companies in the same sector with AI ratings